Cancer Gene Therapy | 2019
SOX17, β-catenin and CyclinD1 expression in the endometrioid adenocarcinoma and influence of 5-AZA on expression
Abstract
The present study discusses the expression and effect of the SOX17 gene in endometrioid adenocarcinoma. MTT assay is performed to determine the growth inhibition ratio of the DNA methyltransferase inhibitor 5-AZA for endometrial carcinoma cells, and the real-time fluorescence quantification PCR (qRT-PCR) was used to detect the mRNA expression of SOX17, β-catenin, and CyclinD1 in endometrial carcinoma tissues before and after using 5-AZA to treat the endometrial carcinoma cell line. There were 30 cases on endometrioid adenocarcinoma tissues and 10 cases on normal endometrial tissues. The results revealed that the expression of SOX17 in endometrioid adenocarcinoma tissues was downregulated ( P \u2009<\u20090.05), the expression of β-catenin and CyclinD1 was upregulated ( P \u2009<\u20090.05), and the expression of SOX17, CyclinD1, and β-catenin was negatively correlated ( r \u2009=\u2009−0.353, P \u2009>\u20090.05; R \u2009=\u2009−0.463, P \u2009<\u20090.05). The higher the histological grade and FIGO staging were, the lower the expression level of SOX17 was ( P \u2009<\u20090.05). After HEC1A cells were treated by 5-AZA, the cell growth inhibition was most obvious (IC 50 \u2009=\u200912.033) at 72\u2009h, as determined by MTT assay. After cell treatment by 5-AZA, the genetic expression of SOX17 significantly increased, when compared with that before treatment ( P \u2009<\u20090.05), while the genetic expression of β-catenin and CyclinD1 significantly declined ( P \u2009<\u20090.05). These results indicate that the expression level of SOX17 in endometrioid adenocarcinoma declined, and the upregulated expression level of SOX17 in cells inhibited the growth of tumor cells.